GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Cyclically Adjusted Price-to-FCF

argenx SE (argenx SE) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


argenx SE Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for argenx SE's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Cyclically Adjusted Price-to-FCF Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of argenx SE's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, argenx SE's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where argenx SE's Cyclically Adjusted Price-to-FCF falls into.



argenx SE Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

argenx SE's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, argenx SE's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.4000*126.4000
=0.000

Current CPI (Dec. 2023) = 126.4000.

argenx SE Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 0.000 99.080 0.000
201312 0.000 98.360 0.000
201403 -0.205 99.390 -0.261
201406 0.017 99.240 0.022
201409 0.000 99.960 0.000
201412 0.000 99.050 0.000
201503 0.000 99.750 0.000
201506 0.000 100.230 0.000
201509 0.000 100.500 0.000
201512 0.000 99.730 0.000
201603 0.000 100.310 0.000
201606 0.000 100.260 0.000
201609 0.000 100.570 0.000
201612 0.000 100.710 0.000
201703 0.000 101.440 0.000
201706 0.000 101.370 0.000
201709 0.000 102.030 0.000
201712 0.000 101.970 0.000
201803 0.000 102.470 0.000
201806 0.000 103.100 0.000
201809 0.000 103.950 0.000
201812 0.000 103.970 0.000
201903 0.000 105.370 0.000
201906 0.000 105.840 0.000
201909 0.000 106.700 0.000
201912 0.000 106.800 0.000
202006 0.000 107.510 0.000
202012 0.000 107.850 0.000
202103 0.000 108.870 0.000
202106 0.000 109.670 0.000
202109 0.000 110.790 0.000
202112 0.000 114.010 0.000
202203 0.000 119.460 0.000
202206 0.000 119.050 0.000
202209 0.000 126.890 0.000
202212 0.000 124.940 0.000
202303 0.000 124.720 0.000
202306 0.000 125.830 0.000
202309 0.000 127.160 0.000
202312 0.000 126.400 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


argenx SE  (NAS:ARGX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


argenx SE Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of argenx SE's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (argenx SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Cyclically Adjusted Price-to-FCF
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.